(Q36512564)

14 August 2017

1 reference

title

Promising new treatments for neovascular age-related macular degeneration (English)

1 reference

14 August 2017

author

Ursula Schmidt-Erfurth

series ordinal

2

object named as

Ursula Schmidt-Erfurth

1 reference

14 August 2017

Stephan Michels

1

1 reference

14 August 2017

Philip J Rosenfeld

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Expert Opinion on Investigational Drugs

14 August 2017

published in

1 reference

14 August 2017

volume

15

1 reference

14 August 2017

issue

7

1 reference

14 August 2017

page(s)

779-793

1 reference

Role of angiogenesis in tumor growth and metastasis

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Current biology of VEGF-B and VEGF-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

The role of vascular endothelial growth factor in ocular health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Solution structure of the heparin-binding domain of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Retinal and choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Complement factor H polymorphism and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Complement factor H variant increases the risk of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Complement factor H polymorphism in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Increased expression of angiogenic growth factors in age-related maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Stimulation of neovascularization by the anti-angiogenic factor PEDF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

RNA interference and potential therapeutic applications of short interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

21 January 2018

Building a better Trap

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Periocular Injection of Microspheres Containing PKC412 Inhibits Choroidal Neovascularization in a Porcine Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Neuroimmunomodulation by macrophage migration inhibitory factor (MIF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intraocular pressure elevation after intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Intraocular gene transfer of pigment epithelium-derived factor rescues photoreceptors from light-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

The burden of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.779

10.1517/13543784.15.7.779

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference